Beth L. Nordstrom
In her role at Evidera, Beth serves as principal investigator on epidemiology and database analytics projects using claims and electronic medical record databases. Her studies have investigated such issues as treatment of chemotherapy-induced anemia, the epidemiology and costs of renal disease in HIV, treatment patterns in multiple sclerosis, and the prevalence of retinal diseases. She has led numerous post-marketing drug safety studies in a wide range of therapeutic areas, including oncology, neurology, rheumatology, and others; outcomes for these studies have also varied widely but include cardiovascular events, renal and hepatic outcomes, and development of cancer.
Prior to joining Evidera, Beth was an epidemiologist at i3 Drug Safety, a division of Ingenix. At i3, she designed and carried out numerous studies related to drug safety and outcomes, including investigations into treatments for HIV, influenza, glaucoma, and psychotic disorders, as well as studies of disease epidemiology in areas such as anemia, atrial fibrillation, and irritable bowel syndrome. Beth’s previous experience includes working in smoking cessation research at Harvard University, running prospective studies of smokers attempting to quit and retrospective epidemiologic studies using data from the Normative Aging Study at the Boston Veteran’s Administration.
Beth earned her a bachelor’s degree from the Massachusetts Institute of Technology and graduate degrees in psychology and public health at Northeastern University and the University of Massachusetts at Amherst.